Kim, Dong Wan
2145  results:
Search for persons X
?
 
?
5

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-R..:

Gettinger, Scott N ; Huber, Rudolf M ; Kim, Dong Wan...
https://research.rug.nl/en/publications/c50d84cd-1e02-472b-88f8-c3f12743c7d7.  , 2022
 
?
 
?
 
?
10

Brigatinib in Crizotinib-Refractory ALK+ NSCLC:2-Year Follo..:

Huber, Rudolf M ; Hansen, Karin H ; Paz-Ares Rodríguez, Luis...
Huber , R M , Hansen , K H , Paz-Ares Rodríguez , L , West , H L , Reckamp , K L , Leighl , N B , Tiseo , M , Smit , E F , Kim , D W , Gettinger , S N , Hochmair , M J , Kim , S W , Langer , C J , Ahn , M J , Kim , E S , Kerstein , D , Groen , H J M & Camidge , D R 2020 , ' Brigatinib in Crizotinib-Refractory ALK+ NSCLC : 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial ' , Journal of Thoracic Oncology , vol. 15 , no. 3 , pp. 404-415 . https://doi.org/10.1016/j.jtho.2019.11.004.  , 2020
 
?
 
?
12

Reduced dose intensity FOLFOX-4 as first line palliative ch..:

Kim, Jee Hyun ; Oh, Do Youn ; Kim, Yu Jung...
Journal of Korean Medical Science, Vol.20 No.5, pp.806-810.  , 2020
 
?
13

Phase II trial of low-dose paclitaxel and cisplatin in pati..:

Lee, Keun-Wook ; Im, Seock Ah ; Yun, Tak...
Japanese Journal of Clinical Oncology, Vol.35 No.12, pp.720-726.  , 2020
 
?
 
1-15